US Patent

US11433041 — Palatable compositions including sodium phenylbutyrate and uses thereof

Formulation · Assigned to Acer Therapeutics Inc · Expires 2036-10-17 · 10y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects palatable pharmaceutical compositions including sodium phenylbutyrate for treating inborn errors of metabolism and neurodegenerative disorders.

USPTO Abstract

The present invention features palatable pharmaceutical compositions including sodium phenylbutyrate and methods for the treatment of inborn errors of metabolism (e.g., Maple Syrup Urine Disease or Urea Cycle Disorders), neurodegenerative disorders such as Parkinson's disease, spinal muscular atrophy, dystonia, or inclusion-body myositis with such compositions.

Drugs covered by this patent

Patent Metadata

Patent number
US11433041
Jurisdiction
US
Classification
Formulation
Expires
2036-10-17
Drug substance claim
No
Drug product claim
Yes
Assignee
Acer Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.